NEWS AND EVENTS
KEEP IN TOUCH WITH US
08 Apr
2020

Aptorum Group uses artifical intelligence to find 3 candidate drugs to treat pneumonia

(Chinese version only) 新冠肺炎仍然肆虐，環球各國都傾盡全力搶救患者並，希望儘快研究出疫苗及有效藥物。本地生物製藥公司並已在美國納斯達克上市的知臨集團（Aptorum）（Nasdaq: APM）就利用大數據平台，找出有潛力的藥物，對付新型肺炎。 知臨集團總裁兼執行董事雷宏業表示，旗下藥物再利用及新藥發現平台Smart-ACTTM，剛完成初步篩選，從超過2,600個獲批准的小分子藥物中選出至少3個針對新型冠狀病毒肺炎 COVID-19 的潛力候選藥物，目前正準備作進一步的臨床前研究。據了解，該3隻有望成為治療新冠肺炎的候選新藥，本來已經存在市場上，但市場上就未有類似的報告顯示能對新型肺炎起作用，因此需要臨床實驗。 新冠肺炎新藥今年底面世雷宏業表示，公司在香港及多倫多均有實驗室，並負責不同臨床實驗。「本次就與位於多倫多的Covar醫療攜手，並與香港大學微生物系達成協議，在為合適的候選藥物尋求監管機構批准以進行臨床試驗之前，實施進一步的臨床前測試。」雷宏業解釋，由於要為藥物做臨床測試，必須要有特別的實驗室，因此與港大微生物學系合作。「因為本次病毒為高傳染性，而實驗室必須符合Level 3（P3）標準，要交予專業團隊負責，因此聯合香港大學微生物學系副教授高一村博士的精英團隊共同合作。」 知臨集團首席醫療總監及執行董事鄭子俊醫生表示，雖然人工智能平台中顯示，該3款候選藥對新冠肺炎有幫助，但目前仍然未知效用有多大，還需待臨床實驗結果出爐才能知道。知臨集團研發部主管李偉業博士表示，臨床實驗的結果將與不同國家及地區的專家組織分享。「希望利用一至兩個月轉入臨床階段，或有望在今年底將藥物面世，並儘快推出市面。」 記者：李彥煒 (Source: https://inews.hket.com/article/2613268/%E3%80%90%E6%96%B0%E5%86%A0%E8%82%BA%E7%82%8E%E3%80%91%E7%9F%A5%E8%87%A8%E9%9B%86%E5%9C%98%E7%94%A8%E4%BA%BA%E5%B7%A5%E6%99%BA%E8%83%BD%E3%80%80%E8%A6%933%E5%80%99%E9%81%B8%E8%97%A5%E7%89%A9%E6%B2%BB%E8%82%BA%E7%82%8E)

Read More
06 Apr
2020

Local Pharma company selects 3 potental candidates, HKU will conduct pre-clinical investigation

(Chinese version only) 本地製藥科研企業知臨集團（Aptorum）上周一（3月30日）公佈，開展針對武漢肺炎病毒的研發項目，並透過大數據平台從逾2,600種已獲批FDA認證的小分子藥物中，初步篩選出3款潛力候選藥物，將交由港大微生物系作進一步的臨床前測試，若證實對治療武漢肺炎有效，冀最快一年內能申請進行新藥臨床試驗（IND）。 知臨集團（Aptorum）上周一（30日）公佈，透過公司大數據平台從逾2,600種已獲批FDA認證的小分子藥物中，初步篩選出3款潛力候選藥物。研發部主管李偉業博士指，會盡快將3種藥物交由港大微生物系作臨床前測試，若數據反映有效治療武漢肺炎，冀最快一年內可申請新藥臨床試驗（IND），屆時亦會公開該3種有效藥物。 知臨集團總裁雷宏業表示，企業與港大微生物系合作，使用港大的P3安全級別實驗室作動物細胞層面研究，惟由於涉及專利問題，目前未能對外公佈3種藥物詳情。他強調市場上未有公司就該3款藥進行研究，該3款藥物或能阻止病毒自我複製，而且因屬於FDA已認證藥物，毋須擔心毒性問題，節省首階段的測試時間。 雷又指，目前有部份國家正使用瑞德西韋（Remdesivir）作治療武漢肺炎的藥物，但在現今疫情大流行情況下，市場需要有多於一款藥物使用，若最終發現3款藥都有效，甚至可應用在不同病情的病人身上，更有效阻隔病毒大規模傳播。 雷又指，在疫情大流行下，美國聯邦食品暨藥物管理局（FDA）或會因應情況加快相關藥物審批，希望最快一年內有成果。他估計該3款潛力候選藥物的測試整體需要50萬至100萬美金，除了向投資者募集資金，亦正向各地政府及私人科研機構申請資助。 (Source: https://hk.appledaily.com/local/20200406/ZVBHMNM2PEPQEG2DA6PGCUVCPY/)

Read More
26 Feb
2020

Expansion of laboratories at Science Park Local biotech companies to benefit

With regard to the 2020 Budget, Financial Secretary Paul Chan Mo Po said that resources will be allocated to spur innovation in Hong Kong, including expansion of the Hong Kong Science Park to support local biotech companies and research institutions. A local biotech company welcomes this move, and plans to expand its scope of R&D and recruit more medical researchers. Founded in Hong Kong, Aptorum Group is a biotech company listed on Nasdaq since 2018, with its R&D headquarter in Hong Kong and a laboratory at the Science Park. Mr. Ian Huen Chung-yuen, founder and Chief Executive Officer of the Group, said that they were currently expanding the laboratory at Science Park. The supportive initiatives of the Budget shall help expand the scale of its R&D activities which will allow more room to house equipment and researchers for medical research development. “We have quite a number of R&D projects progressing rapidly, we’ll therefore need a larger laboratory to cope with our business development,” continued Ian. Recruitment of biomedical doctorate researchers The integration of the Researcher Programme and Postdoctoral Hub was also mentioned in the Budget announcement. Ian said the company had participated in both programmes in the past, and is hoping to be able to reach out to more researchers and professionals through this new integrated platform. “We plan to attract more R&D talents such as biomedical and pharmaceutical doctorate researchers in the next few years, so as to boost momentum for our R&D business and improve our international competitiveness. In recent years, the government has been emphasizing the importance of R&D by subsiding R&D activities and introducing policies encouraging technology transfers from universities to the commercial sector. We welcome these efforts.” Ian added, to operate a biotech company in today’s challenging environment, one must strive to achieve progress and breakthroughs, like the Chinese saying: “A righteous man must strive for ongoing self-improvement”. “Of course, government policies are also crucial to medical research development. We welcome greater support from the government in relevant areas such as rental or R&D subsidies.” (Source: https://inews.hket.com/article/2575085/%E3%80%90%E8%B2%A1%E6%94%BF%E9%A0%90%E7%AE%97%E6%A1%882020%E3%80%91%E7%A7%91%E5%AD%B8%E5%9C%92%E6%93%B4%E5%BB%BA%E5%AF%A6%E9%A9%97%E5%AE%A4%E3%80%80%E6%9C%AC%E5%9C%B0%E7%94%9F%E7%89%A9%E7%A7%91%E6%8A%80%E5%85%AC%E5%8F%B8%E5%8F%97%E6%83%A0)

Read More
×
×
×
×
Terms of Use

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.